Insider Trading & Ownership of Merdad Parsey

Location
Foster City, CA
Summary
The estimated net worth of Merdad Parsey is at least $14,220,177 dollars as of 23 Jun 2025. Merdad Parsey is the Chief Medical Officer of GILEAD SCIENCES, INC. and owns shares of GILEAD SCIENCES, INC. (GILD) stock worth about $13.94M. Merdad Parsey is the Director of ARDELYX, INC. and owns shares of ARDELYX, INC. (ARDX) stock worth about $226.9K. Merdad Parsey is the Director of Sagimet Biosciences Inc. and owns shares of Sagimet Biosciences Inc. (SGMT) stock worth about $52.5K.
Signature
/s/ Elizabeth Grammer, Attorney-in-Fact for Merdad Parsey
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Merdad Parsey and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Merdad Parsey has 4 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $14,220,177.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: GILEAD SCIENCES, INC. ($13,940,850).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Merdad Parsey

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
GILD GILEAD SCIENCES, INC. Chief Medical Officer $13,940,850 10 Dec 2024
ARDX ARDELYX, INC. Director $226,872 18 Jun 2025
SGMT Sagimet Biosciences Inc. Director $52,455 05 Jun 2024
AVBP ArriVent BioPharma, Inc. Director 18 Jun 2025

Insider Transactions Reported by Merdad Parsey:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .